Agilent announces largest acquisition in its history
Agilent Technologies Inc. (Santa Clara, California, USA) has announced that it is to acquire Dako (Glostrup, Denmark), the cancer diagnostic company.
Agilent Technologies Inc. (Santa Clara, California, USA) has announced that it is to acquire Dako (Glostrup, Denmark), the cancer diagnostic company. The $2.2 billion acquisition is the largest in Agilent's history and a significant investment of the company's overseas cash.
Dako provides antibodies, reagents, scientific instruments and software to customers in pathology laboratories to raise the standards for fast and accurate diagnostic answers for cancer patients. They also collaborate with several major pharmaceutical companies to develop new potential pharmacodiagnostics, which can be used to identify patients most likely to benefit from a specific targeted therapy. Dako's products are sold in more than 100 countries.
More than 90% of Dako's business lies in reagants and services and Agilent expect to see their recurring revenues grow from 25% to 30% of total revenue.Bill Sullivan, Agilent president and chief executive officer, said “In the rapidly growing diagnostics market, Dako’s products and capabilities are a strategic complement to Agilent’s existing offerings. Dako is one of the world’s leading providers of cancer diagnostics tools, and together we will be able to develop a wider range of products that help in the fight against cancer. Agilent’s strategy in acquiring Dako is about strengthening the company’s presence in life science and about revenue growth. Dako employs extremely talented people with specialized expertise that we highly value. Their knowledge and experience will be very important as we move forward together.”
Lars Holmkvist, CEO of Dako, said, “Our combined companies will have complementary strengths. Like Agilent, Dako has a long history as a leader in scientific advancement and a culture that values discovery and innovation. We believe that Agilent and Dako are a winning combination.”
The acquisition is expected to close within the next 60 days, subject to the satisfaction of customary closing conditions.
For more information please visit ref="http://www.agilent.com">www.agilent.com
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.
